Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-788 and Midazolam DDI Study in NSCLC
NCT04051827Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 3
01
Overview
Phase 1, open-label trial of mobocertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Geometric Mean Maximum Observed Plasma Concentration for Midazolam, Geometric Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam and 1 more. Started Dec 2019; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04051827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051827.